# Study to Assess Safety & Efficacy of Sitagliptin as Initial Oral Therapy for Treatment of Type 2 Diabetes Mellitus in Pediatric Participants. (MK-0431-083)

> **NCT01485614** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 200 (actual)

## Conditions studied

- Diabetes Mellitus
- Type 2 Diabetes

## Interventions

- **DRUG:** Sitagliptin
- **DRUG:** Metformin
- **DRUG:** Placebo to sitagliptin
- **DRUG:** Placebo to metformin
- **DRUG:** Glycemic Rescue 1
- **BIOLOGICAL:** Glycemic Rescue 2

## Key facts

- **NCT ID:** NCT01485614
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-02-10
- **Primary completion:** 2019-10-09
- **Final completion:** 2019-10-09
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2022-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01485614

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01485614, "Study to Assess Safety & Efficacy of Sitagliptin as Initial Oral Therapy for Treatment of Type 2 Diabetes Mellitus in Pediatric Participants. (MK-0431-083)". Retrieved via MORVS 2026-10-15 from https://api.morvs.ai/clinical/NCT01485614. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*